Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter.
Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 347
Appendix D
Meeting Agendas
Thursday, February 3, 2011
Keck Center of the National Academies
500 Fifth Street, NW
Washington, DC 20001
1:00–1:15 pm Committee Introductions and Chair’s Opening Statement
Jane Henney
Committee Chair
1:10–1:30 pm Charge to the Committee
Lawrence Deyton, M.D., M.S.P.H.
Director
Center for Tobacco Products
U.S. Food and Drug Administration (FDA)
1:30–2:00 pm Discussion About the Charge
Committee and FDA Representatives
2:00–3:00 pm Public Comment
3:00 pm Adjourn
347
OCR for page 348
348 STUDIES ON MODIFIED RISK TOBACCO PRODUCTS
Monday, May 9, 2011
Embassy Suites
900 Tenth Street, NW
Washington, DC 20001
9:45–10:00 am Welcome and Introductions
Jane Henney
Committee Chair
10:00–11:30 am Panel Discussion I: Tobacco Manufacturers
Moderator: Peter Honig
10:00–11:00 am: Presentations by industry representatives
11:00–11:30 am: Questions from the Committee
• Introduction
Standards for pre-clinical studies
Mike Ogden
Senior Director of Regulatory Oversight
R.J. Reynolds Tobacco Company
• Standards for studies on in vitro models of disease
Chris Proctor
Chief Scientific Officer
British American Tobacco
• Standards for clinical studies and biomarkers
Mohamadi Sarkar
Senior Principal Research Scientist
Altria Client Services
• Population communication and risk perception
Lars Erik Rutqvist
Senior Vice President for Scientific Affairs
Swedish Match
• Summary
J. Daniel Heck
Principal Scientist
Lorillard Tobacco Company
OCR for page 349
349
APPENDIX D
11:30 am– Andrew Salmon
12:00 pm Senior Toxicologist and Chief
Air Toxicology and Risk Assessment Section
Office of Environmental Health Hazard Assessment
California Environmental Protection Agency
12:00–1:00 pm Lunch
1:00–1:30 pm David Jacobson-Kram
Associate Director of Pharmacology and Toxicology
Office of New Drugs
Food and Drug Administration
1:30–2:00 pm Peter G. Shields
Professor of Medicine and Oncology
Deputy Director, Lombardi Comprehensive Cancer Center
Georgetown University
Mirjana Djordjevic
Health Scientist Administrator
Tobacco Control Research Branch
National Cancer Institute
2:00–2:30 pm John Baron
Professor of Medicine
Dartmouth Medical School
2:30–2:45 pm Break
2:45–3:15 pm Brenda Edwards
Associate Director
Surveillance Research Program
National Cancer Institute
3:15–3:45 pm Ruth S. Day
Director
Medical Cognition Laboratory
Duke University
3:45–4:15 pm David Mendez
Associate Professor
Department of Health Management and Policy
University of Michigan School of Public Health
OCR for page 350
350 STUDIES ON MODIFIED RISK TOBACCO PRODUCTS
4:15–4:30 pm Break
4:30–6:00 pm Panel Discussion II: public health representatives
Moderator: Dan Carpenter
4:30–5:30 pm: Presentations by public health
representatives
5:30–6:00 pm: Questions from the Committee
• David Abrams
Executive Director
The Schroeder Institute for Tobacco Research and Policy
Studies
Professor, Department of Health, Behavior and Society
The Johns Hopkins Bloomberg School of Public Health
• Tom Glynn
Director, Cancer Science and Trends
Director, International Cancer Control
American Cancer Society
• Mark Greenwold
Director, Regulatory Affairs
Campaign for Tobacco-Free Kids
• Rose Marie Robertson
Chief Science Officer
American Heart Association
• Mitch Zeller
Vice President for Policy and Strategic Communications
Pinney Associates
6:00 pm Adjourn
